Jabbar, Karolina S.
Priya, Sambhawa
Xu, Jiawu https://orcid.org/0000-0002-0424-0736
Das Adhikari, Upasana
Pishchany, Gleb
Mohamed, Ahmed T. M. https://orcid.org/0000-0003-2390-2210
Johansen, Joachim
Thurimella, Kumar
McCabe, Cristin
Vlamakis, Hera
Okello, Samson
Delorey, Toni M. https://orcid.org/0000-0001-6614-3803
Lankowski, Alexander https://orcid.org/0000-0002-4769-7242
Mosepele, Mosepele
Siedner, Mark J.
Plichta, Damian R. https://orcid.org/0000-0002-6555-2557
Kwon, Douglas S. https://orcid.org/0000-0001-8521-8735
Xavier, Ramnik J. https://orcid.org/0000-0002-5630-5167
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 DK043351)
U.S. Department of Health & Human Services | National Institutes of Health (R01 HL141053)
U.S. Department of Health & Human Services | National Institutes of Health (K24 HL166024)
U.S. Department of Health & Human Services | National Institutes of Health (DK120485)
Article History
Received: 1 April 2024
Accepted: 5 September 2025
First Online: 30 October 2025
Competing interests
: R.J.X. is a co-founder of Jnana Therapeutics and Convergence Bio, board director at MoonLake Immunotherapeutics, a consultant to Nestlé and a member of the advisory boards at MagnetBiomedicine and Arena Bioworks. The other authors declare no competing interests.